🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Unresectable Pancreatic Cancer

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer NCT06984562NA1 site📍 Philadelphia Fox Chase Cancer Center · Tests: Adaptive Radiation Therapy A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer NCT05365581Phase 146 sites📍 Orange📍 Santa Monica📍 Chicago Astellas Pharma Global Development, Inc. · Tests: ASP2138, Pembrolizumab, Oxaliplatin, Leucovorin, Fluorouracil CT-95 in Advanced Cancers Associated With Mesothelin Expression NCT06756035Phase 19 sites📍 Denver📍 Chicago📍 Grand Rapids Context Therapeutics Inc. · Tests: CT-95 Surgery for Locally Unresectable Pancreatic Cancer NCT07241663n/a1 site📍 Padova Azienda Ospedaliera di Padova · Tests: Questionnaire TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma NCT07189195Phase 11 site📍 Sacramento University of California, Davis · Tests: TR-002 A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation NCT06778863Phase 121 sites📍 Scottsdale📍 Tucson📍 Los Angeles Clasp Therapeutics, Inc. · Tests: CLSP-1025 A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors NCT07488676Phase 1, Phase 221 sites📍 Birmingham📍 Los Angeles📍 Miami Astellas Pharma Global Development, Inc. · Tests: ASP546C OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry. NCT04493632n/a9 sites📍 Las Palmas de Gran Canaria📍 Madrid📍 Madrid OncoSil Medical Limited Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328Phase 3333 sites📍 Gilbert📍 Gilbert📍 Peoria NRG Oncology · Tests: Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer NCT07539155Phase 1, Phase 21 site📍 Little Rock University of Arkansas · Tests: Intratumoral MMR Injection A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors NCT07066657Phase 121 sites📍 Los Angeles📍 San Francisco📍 Aurora ArriVent BioPharma, Inc. · Tests: MRG007, MRG007 and Bevacizumab Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" NCT01365169NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: Exercise Intervention, Health Telemonitoring, Health Telemonitoring, Health Telemonitoring, Health Telemonitoring Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors NCT07523529Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients NCT06359275Phase 21 site📍 Shanhai Fudan University · Tests: PD-1, Nab-paclitaxel, Gemcitabine, PULSAR Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer NCT07235930Phase 31 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: Sequential AG and mFOLFOX in Combination With Serplulimab and Bevacizumab, AG chemotherapy A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204Phase 120 sites📍 Santa Monica📍 Atlanta📍 Jefferson Astellas Pharma Inc · Tests: ASP5834, panitumumab IRE After Chemotherapy for Locally Advanced Pancreatic Cancer NCT07799935NA1 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: IRE, PLACEBO Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer NCT07575191Phase 1, Phase 21 site📍 Solna Smartwise Sweden AB · Tests: Gemcitabine, Extroducer Infusion Catheter System A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569Phase 114 sites📍 Orlando📍 Tampa📍 Boston Alterome Therapeutics, Inc. · Tests: ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy NCT05988814Phase 21 site📍 Dijon Centre Georges Francois Leclerc · Tests: FOLFIRINOX treatment Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer NCT06605430Phase 21 site📍 Saint Louis Park HealthPartners Institute · Tests: Medical Cannabis A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation NCT07784374Phase 21 site📍 Shanghai Genfleet Therapeutics (Shanghai) Inc. · Tests: GFH375, GFH276, GFS202A Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety) NCT05657743NA2 sites📍 Holon📍 Jerusalem Alpha Tau Medical LTD. · Tests: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors NCT06943755Phase 2, Phase 3133 sites📍 Birmingham📍 Phoenix📍 Tucson Exelixis · Tests: Zanzalintinib, Everolimus Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors NCT05053971Phase 1, Phase 23 sites📍 New Haven📍 Gainesville📍 Oklahoma City National Cancer Institute (NCI) · Tests: BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy, Entinostat NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer NCT07595172Phase 1, Phase 21 site📍 Chengdu West China Hospital · Tests: NALIRIFOX+Adebrelimab, PULSAR A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer NCT07481383Phase 12 sites📍 Ann Arbor📍 Morgantown Continuity Biosciences, LLC · Tests: ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003) Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations NCT06998940Phase 3274 sites📍 Anchorage📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Biospecimen Collection, Computed Tomography, Fluorouracil, Gemcitabine, Irinotecan Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas NCT02598349Phase 24 sites📍 Little Rock📍 Jacksonville📍 Warrenville Proton Collaborative Group · Tests: Proton Radiation, Capecitabine, Surgical resection D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC NCT06643208n/a1 site📍 Fuzhou Fujian Provincial Hospital · Tests: TACE-HAIC, Envafolimab and Lenvatinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy